Genetic Variants and Response to GLP-1 Treatments
A large-scale analysis involving nearly 28,000 participants from a consumer DNA-testing database examined how inherited genetic differences may influence outcomes from GLP-1 receptor agonist medications used for obesity and diabetes management. The findings indicate that variation in the GLP1R gene, which encodes the receptor targeted by these drugs, is associated with differences in weight reduction during treatment.
Individuals carrying a single copy of a specific GLP1R variant experienced an average additional weight loss of approximately 1.7 pounds (0.76 kg) over a median treatment period of eight months compared to non-carriers. Participants with two copies of the same variant showed an average additional reduction of about 3.3 pounds. Although statistically measurable, the overall magnitude of this effect was described as modest.
The research also identified associations between certain GLP1R gene mutations and gastrointestinal side effects, including nausea and vomiting. In addition, another gene, GIPR, which is involved in insulin secretion and energy balance, was associated with increased risk of vomiting in individuals receiving tirzepatide therapy, a medication used for type 2 diabetes and obesity treatment.
In the subgroup receiving tirzepatide, carriers of the identified GIPR variant were reported to have an 83% higher likelihood of experiencing vomiting compared with non-carriers. Researchers emphasized that genetic influences on treatment response exist but are generally limited in size. They suggested that variations in drug-target genes may contribute to differences among patients and could support future approaches in precision medicine for weight management therapies.
Cardiovascular Outcomes Independent of Weight Reduction
A separate study evaluated 47,199 patients with established cardiovascular disease who were treated with semaglutide, a GLP-1 receptor agonist used under different formulations for diabetes and obesity management. Participants were followed for up to two years after treatment.
The analysis confirmed that higher medication doses were associated with greater weight loss, consistent with expectations. However, researchers found that cardiovascular benefits observed in patients did not correlate with the amount of weight reduction achieved during treatment.
Two years after therapy ended, individuals who had received higher doses showed reduced risks across several clinical outcomes. These included overall mortality, myocardial infarction, stroke, cardiovascular-related death, cerebral vascular blockage, heart failure, and heart valve disorders. The results suggest that improvements in cardiovascular health may occur independently of body weight changes.
Tissue analysis indicated that GLP-1 receptor proteins are most abundant in the pancreas, with significant presence also detected in cardiac tissue. Researchers proposed that this distribution may suggest a potential direct effect of the medication on the heart, although this remains a hypothesis requiring further investigation. The study authors noted that the lack of correlation between weight loss and cardiovascular benefit supports the need for additional research into the biological mechanisms involved.
Single DNA Change and Sex Development in Mice
A third study demonstrated that a single mutation in a non-coding regulatory DNA region can alter sex development in mice. Researchers focused on XX mouse embryos, which typically develop as females, and introduced a targeted change using CRISPR-based genome editing.
The modification was applied to a regulatory region known as Enh13, which controls the activity of the Sox9 gene. Sox9 plays a critical role in testis formation, but is normally suppressed during female development. Following the mutation, this suppression mechanism failed, resulting in activation of Sox9 and initiation of testis development.
The affected embryos developed male internal and external reproductive characteristics despite carrying XX chromosomes. The change involved a single nucleotide alteration within a genome of approximately 2.8 billion base pairs, demonstrating that minimal variation in regulatory DNA can produce significant developmental effects.
Researchers highlighted that around 98% of the genome consists of non-coding DNA, which regulates gene expression rather than encoding proteins. The findings emphasize the functional importance of these regulatory regions in biological development and disease mechanisms.
The study may contribute to understanding Differences of Sex Development, which occur in an estimated one in 4,000 births worldwide. More than half of these cases currently lack a genetic diagnosis even after analysis of protein-coding regions. The results suggest that disease-causing variants may reside outside traditional gene-coding sequences, within regulatory DNA elements that control gene activity.